Status:
UNKNOWN
The Heartflow Coronary Disease Progression Evaluation Study
Lead Sponsor:
Erasmus Medical Center
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
Invasively measured fractional flow reserve (FFR) has proven to be useful in guiding coronary revascularization. Several studies have shown that it is justified to treat lesions with a value of 0.80 o...
Eligibility Criteria
Inclusion
- Patients (age ≥ 18 years) treated with PCI (for non-ST elevation myocardial infarction, unstable or stable angina and silent ischemia) or who undergo invasive FFR.
- Minimum of one non-treated coronary artery with an intermediate lesion and invasive FFR 0.81-0.90 to serve as the target vessel for FFRCT.
Exclusion
- ST elevation myocardial infarction.
- Previous CABG.
- Target vessel for FFR measurement \< 2.0 mm in diameter.
- Contraindications to contrast agents, beta-blocking agents, nitroglycerin or adenosine.
- Life expectancy less than 3 years.
- Creatinine clearance \< 30 ml/min\*1.73m2.
Key Trial Info
Start Date :
October 5 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04052256
Start Date
October 5 2018
End Date
October 1 2023
Last Update
July 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, Netherlands